Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a predominantly type 2 inflammation-mediated disease of the nasal mucosa and paranasal sinuses. The disease is characterised grossly by grape-like projections of inflammatory polyps within the nasal cavity. CRSwNP is known to cause a significant burden to quality of life, result in significant health care expenditures, and has been demonstrated to have an impact on cognitive function. Current management strategies for CRSwNP employ a combination both of medical and surgical interventions to alleviate disease burden and provide symptom control. In particular, the advent of targeted biologics has shown promise in targeting different aspects of the inflammatory pathway associated with CRSwNP.

On 30th June, 2022, a webinar titled “Biologics Treatment in CRSwNP  – The Principles and Local Experiences” was successfully organised by the Hong Kong Society of Otorhinolaryngology, Head and Neck Surgery. In the event, Dr Raymond Tso, specialist in respiratory medicine, was invited to highlight the pathophysiology and clinical management of severe asthma with CRSwNP. To illustrate the practical details in managing CRSwNP comorbid with biologics, Dr Yau Kay Chung Julian, specialist in otorhinolaryngology, presented the case of a patient who suffered from asthma with nasal polyp. In the case, 3-week biologics treatment yielded promising outcome in reducing nasal polyps.
 

Discussion between participants and keynote speakers was moderated by Dr. Dennis Lee (right)

Dr. Julian Yau presented the biomarkers of CRSwNP

Dr. Raymond Tso presented the outcomes of biologics treatment in severe asthma with CRSwNP

Dupilumab was demonstrated to effectively improve symptoms of CRSwNP

Dr. Raymond Tso outlined the recommendations on biologics treatment in severe asthma

Presentation of practical efficacy of biologics treatment